Heavy Metal Wonder
An iridium-based photodynamic drug accumulates in cancer cell nuclei – and destroys them from within
Jonathan James | | Quick Read
After the approval of cisplatin in the late 1970s, scientists struggled to replicate the success with other heavy metal-based chemotherapeutics. But, more recently, the field has seen somewhat of a resurgence with new metal-based compounds boasting distinct modes of action (1). Now, a paper in the international edition of the German journal Angewandte Chemie highlights a new photosensitizer with iridium at its core (2).
Read the full article now
Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.
- U Ndagi et al., “Metal complexes in cancer therapy – an update from a drug design perspective.” Drug Des Devel Ther. 11, 599-616. (2017) PMID: 28424538.
- P Zhang et al., “Nucleus-Targeted Organoiridium-Albumin Conjugate for Photodynamic Cancer Therapy.” Angew Chem Int Ed Engl. [Epub ahead of print] (2018) PMID: 30552796.
- J Trachtenberg et al., “Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response”, J Urol. 178, 1974-1979 (2007). PMID: 17869307.
- T Gheewala, T Skwor & G Munirathinam, “Photosensitizers in prostate cancer therapy”, Oncotarget. 8, 30524-30538 (2017). PMID: 28430624.